Susan Desmond-Hellmann Net Worth

The estimated Net Worth of Susan Desmond Hellmann is at least $2.21 Milhão dollars as of 15 May 2019. Susan Hellmann owns over 1,640 units of Pfizer stock worth over $974,450 and over the last 12 years he sold PFE stock worth over $1,237,467. In addition, he makes $0 as Director at Pfizer.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Susan Hellmann PFE stock SEC Form 4 insiders trading

Susan has made over 30 trades of the Pfizer stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 1,640 units of PFE stock worth $48,642 on 15 May 2019.

The largest trade he's ever made was exercising 6,243 units of Pfizer stock on 15 May 2015 worth over $185,167. On average, Susan trades about 861 units every 35 days since 2012. As of 15 May 2019 he still owns at least 32,854 units of Pfizer stock.

You can see the complete history of Susan Hellmann stock trades at the bottom of the page.

Susan Desmond-Hellmann biography

Dr. Susan D. Desmond-Hellmann M.D. serves as Director of the Company. Dr. Desmond-Hellmann served as Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 until 2020, where she oversaw the creation of the Gates Medical Research Institute—the world’s first nonprofit biotech organization—as well as the launch of the Economic Mobility and Opportunity investment strategy in the U.S. She remains a Senior Advisor and Board member of the Gates Medical Research Institute. Prior to joining the Bill & Melinda Gates Foundation, she was the first female and ninth overall Chancellor of the University of California, San Francisco (UCSF) from 2009 until 2014, where she still serves as an adjunct professor. From 1995 through 2009, Dr. Desmond-Hellmann was employed at Genentech where she served as President of Product Development, from 2005-2009 overseeing pre-clinical and clinical development, business development and product portfolio management. Prior to joining Genentech, Dr. Desmond-Hellmann was Associate Director, Clinical Cancer Research at Bristol-Myers Squibb Pharmaceutical Research Institute. She served as a Director of Facebook Inc. from 2013 to 2019 and Procter & Gamble from 2010 to 2017. Dr. Desmond-Hellmann received a B.S. in Pre-Med and an M.D. from the University of Nevada and a M.P.H. from the University of California, Berkeley.

How old is Susan Hellmann?

Susan Hellmann is 62, he's been the Director of Pfizer since 2020. There are 6 older and 22 younger executives at Pfizer. The oldest executive at Pfizer Inc. is Wyllie Don Cornwell, 72, who is the Independent Director.

What's Susan Hellmann's mailing address?

Susan's mailing address filed with the SEC is 66 HUDSON BOULEVARD EAST, ATTN: CORPORATE SECRETARY, NEW YORK, NY, 10001-2192.

Insiders trading at Pfizer

Over the last 12 years, insiders at Pfizer have traded over $216,003,942 worth of Pfizer stock and bought 24,324 units worth $872,198 . The most active insiders traders include Shantanu Narayen, Ian C Read, eJames M Kilts. On average, Pfizer executives and independent directors trade stock every 12 days with the average trade being worth of $2,169,896. The most recent stock trade was executed by Jennifer B. Damico on 13 August 2024, trading 5,154 units of PFE stock currently worth $147,714.

What does Pfizer do?

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.

Complete history of Susan Hellmann stock trades at Meta Platforms Inc, Pfizer, eProcter & Gamble Co

Pfizer executives and stock owners

Pfizer executives and other stock owners filed with the SEC include:

• Albert Bourla,
  Chairman of the Board, Chief Executive Officer
• Frank D'Amelio,
  Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
• Mikael Dolsten,
  Chief Scientific Officer, President - Worldwide Research, Development and Medical
• John Young,
  Chief Business Officer, Group President
• Dr. Albert Bourla D.V.M., DVM, Ph.D.,
  Chairman & CEO
• Frank A. D'Amelio,
  CFO & Exec. VP
• Dr. Mikael Dolsten M.D., Ph.D.,
  Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical
• Angela Hwang,
  Group Pres of Biopharmaceuticals Group
• John D. Young,
  Advisor
• Shantanu Narayen,
  Lead Independent Director
• Wyllie Don Cornwell,
  Independent Director
• Helen Hobbs,
  Independent Director
• Suzanne Nora Johnson,
  Independent Director
• Joseph Echevarria,
  Independent Director
• James Kilts,
  Independent Director
• Ronald Blaylock,
  Independent Director
• Dan Littman,
  Independent Director
• Scott Gottlieb,
  Independent Director
• James Quincey,
  Independent Director
• Susan Hockfield,
  Independent Director
• Susan Desmond-Hellmann,
  Director
• Gordon Loh,
  Senior Vice President, Corporate Audit
• Jennifer Damico,
  Senior Vice President, Principal Accounting Officer, Controller
• Sally Susman,
  Chief Corporate Affairs Officer, Executive Vice President
• Alexander Mackenzie,
  Executive Vice President, Chief Development Officer
• Douglas Lankler,
  Executive Vice President, General Counsel
• Rady Johnson,
  Chief Compliance, Quality and Risk Officer, Executive Vice President
• Lidia Fonseca,
  Executive Vice President, Chief Technology Officer and Digital Officer
• Dawn Rogers,
  Chief Human Resource Officer, Executive Vice President
• Angela Hwang,
  Group President, Pfizer Biopharmaceuticals Group
• Rady A. Johnson,
  Exec. VP and Chief Compliance, Quality & Risk Officer
• Douglas M. Lankler,
  Exec. VP & Gen. Counsel
• Christopher J. Stevo CFA,
  Sr. VP & Chief Investor Relations Officer
• Lidia L. Fonseca,
  Exec. VP and Chief Digital & Technology Officer
• Jennifer B. Damico,
  Sr. VP, Controller & Principal Accounting Officer
• Mike McDermott,
  Chief Financial Officer
• William Pao,
  Executive Vice President
• Stephen W Sanger,
  Director
• Frances D Fergusson,
  Director
• James C Smith,
  Director
• Laurie J Olson,
  Executive Vice President
• W Don Cornwell,
  Director
• Loretta V Cangialosi,
  Sr. Vice President, Controller
• Charles H Hill,
  Executive Vice President
• Dennis A Ausiello,
  Director
• Kirsten Lund Jurgensen,
  Executive Vice President
• Ian C Read,
  Chairman & CEO
• Freda C Lewis Hall,
  Executive Vice President
• Aamir Malik,
  Executive Vice President
• Christoffel Boshoff,
  Executive Vice President
• Michael Goettler,
  Group President
• Cyrus Taraporevala,
  Director
• Iii William H Gray,
  Director
• M Anthony Burns,
  Director
• Cavan M. Redmond,
  Group President
• Kristin C Peck,
  Executive Vice President
• David S Simmons,
  Business Unit President
• Geno J Germano,
  Business Unit President
• Anthony J Maddaluna,
  Executive Vice President
• Olivier Brandicourt,
  Business Unit President
• Marc Tessier Lavigne,
  Director
• George A Lorch,
  Director
• Amy W Schulman,
  Executive Vice President
• Constance J Horner,
  Director
• Payal Sahni,
  Executive Vice President
• William R Jr Carapezzi,
  Executive Vice President
• Michael Mc Dermott,
  Executive Vice President
• David M Denton,
  Chief Financial Officer & EVP